Lenalidomide vs Observation for Asymptomatic High-Risk Smoldering Multiple Myeloma

When should smoldering multiple myeloma patients start treatment?Подробнее

Phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk SMMПодробнее

Phase III trial of lenalidomide vs observation alone in pts with asymptomatic high-risk SMMПодробнее

Clinical Trials’ Impact on Smoldering Myeloma ManagementПодробнее

Treatments Available for High Risk Smoldering Myeloma PatientsПодробнее

Dr. Sagar Lonial on Lenalidomide Versus Observation in Smoldering MyelomaПодробнее

Evidence supporting lenalidomide for high-risk smoldering myeloma patientsПодробнее

Smoldering Myeloma: Who and when to treat?Подробнее

Multiple Myeloma Precursor Conditions | Overview | Therapeutic InterventionПодробнее

Lenalidomide for smoldering myelomaПодробнее

Dr. Sagar Lonial on Treating Patients With Smoldering Multiple MyelomaПодробнее

High Risk and Smoldering Multiple MyelomaПодробнее

Case 1: Patient with high-risk smoldering myelomaПодробнее

What are the latest advances in treating high-risk smoldering myeloma?Подробнее

Smoldering multiple myeloma: Early detection and intervention approaches by Dr. Mark BustorosПодробнее

Managing High-Risk Smoldering MyelomaПодробнее

Dr. Mark Bustoros discusses clinical trial results for high-risk smoldering multiple myelomaПодробнее

High-Risk Smoldering Multiple Myeloma: Systemic TherapyПодробнее

Smoldering myeloma: Who and when to treat?Подробнее

Daratumumab, Carfilzomib, Lenalidomide and Dex for HR Smoldering Multiple Myeloma: ASCENT TrialПодробнее